Cargando…

Immune-related endocrine disorders in novel immune checkpoint inhibition therapy

Immune checkpoint inhibition against advance malignancies was named breakthrough discovery by the science magazine in 2013. In numerous clinical studies, monoclonal antibodies against the immune checkpoints, CTLA4, PD1 and PD1 ligand PDL1 have shown promising tumor response in different type of meta...

Descripción completa

Detalles Bibliográficos
Autor principal:	Min, Le
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Chongqing Medical University 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881952/ https://www.ncbi.nlm.nih.gov/pubmed/29623291 http://dx.doi.org/10.1016/j.gendis.2016.10.002

Ejemplares similares

Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy
por: Chye, Adrian, et al.
Publicado: (2022)

The side effects of immune checkpoint inhibitor therapy on the endocrine system
por: Goyal, Itivrita, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society
por: Kwon, Hyemi, et al.
Publicado: (2022)

Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review
por: Stelmachowska-Banaś, Maria, et al.
Publicado: (2020)

Endocrine side effects of immune checkpoint inhibitors
por: Cardona, Zulma, et al.
Publicado: (2023)

Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment
por: Chieng, Jenny Hui Ling, et al.
Publicado: (2022)

Clinical diagnosis and treatment of immune checkpoint inhibitors‐related endocrine dysfunction
por: Duan, Lian, et al.
Publicado: (2020)

Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
por: Husebye, Eystein S, et al.
Publicado: (2022)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
por: Girotra, Monica, et al.
Publicado: (2018)

Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
por: Badran, Yousef R, et al.
Publicado: (2023)

SAT-491 Transient Thyrotoxicosis with Immune Checkpoint Inhibitors Therapy: The Importance of Endocrine Evaluation
por: Martins, Diana Cruz, et al.
Publicado: (2020)

How we treat endocrine complications of immune checkpoint inhibitors
por: Paschou, S.A., et al.
Publicado: (2021)

Immune checkpoint inhibitors, endocrine adverse events, and outcomes of melanoma
por: Karhapää, Hanna, et al.
Publicado: (2022)

Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
por: Oppolzer, Immanuel Augustin, et al.
Publicado: (2023)

FRI539 Vitamin D and Endocrine Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitors
por: He, Zijun, et al.
Publicado: (2023)

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
por: Illouz, Frédéric, et al.
Publicado: (2017)

Cardiac Complications in Immune Checkpoint Inhibition Therapy
por: Tajiri, Kazuko, et al.
Publicado: (2019)

Immune checkpoint: The novel target for antitumor therapy
por: Jiang, Xianghu, et al.
Publicado: (2019)

Immune checkpoint inhibitor therapy for pediatric cancers: A mini review of endocrine adverse events
por: Ihara, Kenji
Publicado: (2019)

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition
por: Henderson Berg, Meagan-Helen, et al.
Publicado: (2022)

Inhibition of APOE potentiates immune checkpoint therapy for cancer
por: Hui, Bingqing, et al.
Publicado: (2022)

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

TIGIT, a novel immune checkpoint therapy for melanoma
por: Tang, Wei, et al.
Publicado: (2023)

Endocrine Toxicity and Outcomes in Patients With Metastatic Malignancies Treated With Immune Checkpoint Inhibitors
por: Al Ashi, Suleiman I, et al.
Publicado: (2021)

HDAC Inhibition to Prime Immune Checkpoint Inhibitors
por: Borcoman, Edith, et al.
Publicado: (2021)

PCSK9 inhibition potentiates cancer immune checkpoint therapy
por: Liu, Xinjian, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
por: Chen, Ru, et al.
Publicado: (2022)

Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review
por: Hwang, Sung Wook, et al.
Publicado: (2023)

Monalizumab: inhibiting the novel immune checkpoint NKG2A
por: van Hall, Thorbald, et al.
Publicado: (2019)

Immune checkpoint inhibition: prospects for prevention and therapy of hepatocellular carcinoma
por: Elsegood, Caryn L, et al.
Publicado: (2017)

Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
por: Peyraud, Florent, et al.
Publicado: (2020)

Immune checkpoint inhibition mediated with liposomal nanomedicine for cancer therapy
por: Ma, Guang-Long, et al.
Publicado: (2023)

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors
por: Iwama, Shintaro, et al.
Publicado: (2021)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
por: Glehr, Gunther, et al.
Publicado: (2022)

Age-Related Differences in Molecular Profiles for Immune Checkpoint Blockade Therapy
por: Zhang, Qi-jie, et al.
Publicado: (2021)

Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies
por: Kerepesi, Csaba, et al.
Publicado: (2020)

Neurosarcoidosis following Immune Checkpoint Inhibition
por: Dunn-Pirio, Anastasie M., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5o9ufc8kfe52qel78ec9bt99s1